

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrop⦠read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
$28.95
Price+0.52%
$0.15
$2.783b
Mid
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$0.00
-
1y CAGR-33.3%
3y CAGR-5.9%
5y CAGR-$315.687m
-28.2%
1y CAGR-34.2%
3y CAGR-25.6%
5y CAGR-$2.98
-20.6%
1y CAGR-11.6%
3y CAGR+0.9%
5y CAGR$233.293m
$340.045m
Assets$106.752m
Liabilities$61.529m
Debt18.1%
-0.2x
Debt to EBITDA-$258.123m
-28.4%
1y CAGR-25.1%
3y CAGR-19.2%
5y CAGR